Loading...
Angiogenesis is now a validated target in advanced colorectal cancer (CRC), with three agents (bevacizumab, aflibercept, and regorafenib) now available in clinical practice as part of first-, second-, and later-line therapy. Continued suppression of the vascular endothelial growth factor (VEGF) pathway into serial lines of therapy in CRC has been validated in clinical trials. An alternative approach that directly targets the VEGF receptor 2 (VEGFR2) by using a ligand binding site blocking antibody is achieved by the drug ramucirumab.
Investigators now report results of an industry-sponsored, international, multicenter, randomized, double-blind, placebo-controlled phase III trial (RAISE) of ramucirumab involving 1072 patients with metastatic …